Supreme Court rejects Martin Shkreli fine appeal

• The Supreme Court on Monday rejected a bid by notorious "pharma bro" Martin Shkreli to hear his appeal of a $64 million financial penalty on the fraudster.
• Shkreli had been ordered to pay that penalty for blocking competition to a lifesaving drug whose price he had raised by more than $700 per pill.
• Shkreli's request that the Supreme Court take his appeal of a federal court decision on a lawsuit by the Federal Trade Commission was his last chance to overturn that penalty, which was related to the drug Daraprim.

The Supreme Court on Monday rejected a bid by notorious 'pharma bro' Martin Shkreli to hear his appeal of a $64 million financial penalty on the fraudster for blocking competition to a lifesaving drug whose price he had raised by more than $700 per pill.

Shkreli's request that the Supreme Court take his appeal of a federal court decision was his last chance to overturn the penalty related to the drug Daraprim.

The Supreme Court in rejecting that request did not explain its reason for doing so. There were no noted dissents by any justice to the decision.

Shkreli's lawyer had asked the Supreme Court to take the appeal to resolve a so-called circuit split between the appeals court that upheld his financial penalty and two other federal appeals court circuits that the attorney said would have limited his financial liability in the case.

The attorney, Thomas Huff, told CNBC, "Although we were disappointed in the disposition, we also think it is just a matter of time before the Supreme Court overturns the Second Circuit's outlier approach to equitable disgorgement — an approach that in this case permitted a district court to order Mr. Shkreli to 'disgorge' over $64 million in profits that never touched his possession or